Head-to-head · Cost-Efficiency Index
Rewinding RX vs AbundRX
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
Rewinding RX
Shoppers who want a flat, no-dose-upcharge price and are comparing the standard-dose product specifically, not the cheaper microdose line.
Visit Rewinding RXAbundRX
Cost-first shoppers, with the caveat that the advertised price's time period is unconfirmed.
Visit AbundRXThe verdict
Rewinding RX takes it, leading the Cost-Efficiency Index 66 to 65. Rewinding RX (Rewinding RX Ltd.) is a longevity-framed telehealth platform selling FOUR distinct GLP-1 products: standard-dose semaglutide ($139/mo) and tirzepatide ($189/mo). AbundRX still earns a C — Cost-first shoppers, with the caveat that the advertised price's time period is unconfirmed.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the ranking). See how it stacks up: CoreAge Rx vs Rewinding RX.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | Rewinding RX | AbundRX |
|---|---|---|
| Cost-Efficiency Index | 66/100 | 65/100 |
| Semaglutide / mo | $139/mo (microdose tier, compounded) | $99/mo (starting dose, compounded) |
| Tirzepatide / mo | $189/mo (microdose tier, compounded) | $149/mo (starting dose, compounded) |
| Semaglutide / yr (modeled) | $1,668 | $1,188 |
| Tirzepatide / yr (modeled) | $2,268 | $1,788 |
| Coverage | All 50 states | Coverage not published |
| Oral / sublingual | No | No |
| Brand-name access | Compounded only | Compounded only |
| Rank here | #150 | #157 |
Rewinding RX
66/100Where the value is
- Flat pricing within each product regardless of dose
- Publishes the FDA compounded-medication disclaimer and states pharmacies are '503A'/'503B' FDA-regulated facilities
- Corporate entity is disclosed (Rewinding RX Ltd.)
The tradeoffs
- Four separate GLP-1 SKUs exist at four different prices under similar names
- No compounding pharmacy is individually named, only generic '503A'/'503B' language
AbundRX
65/100Where the value is
- LegitScript certification badge confirmed present on the live homepage
- Simple, fast online health assessment with two clear compounded GLP-1 pathways
- Genuinely low advertised entry price ($99 semaglutide / $149 tirzepatide) as verified directly from the site's own product cards — cheaper than the figure currently on file
The tradeoffs
- The site does not state whether '$99'/'$149' is a monthly, one-time, or first-order price — no duration label appears anywhere near either figure
- No dose amount or supply quantity is disclosed for either price
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.